Xenon Pharmaceuticals Inc. - Common Shares (XENE)
XENE moved a median of +0.03% 30 minutes after news, and -0.62% by the close. How XENE actually reacts to news — the realized, point-in-time move the market made, measured across 276 labeled events over the last three years with zero look-ahead.
XENE’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 49% | 276 |
| 30-min | +0.03% | 50% | 276 |
| 60-min | -0.18% | 48% | 276 |
| to close | -0.62% | 36% | 272 |
| Middle 50% of XENE reactions | -0.90% to +0.99% |
|---|---|
| Median reaction (30-min) | +0.03% |
| Measured reactions | 276 |
Half of all Xenon Pharmaceuticals Inc. - Common Shares news events land between -0.90% and +0.99% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How XENE reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 24 | -0.07% | 38% | -0.11% |
| Rating reiterations | 98 | -0.32% | 42% | -1.25% |
| Price-target raises | 21 | -0.12% | 38% | -0.38% |
| Price-target cuts | 17 | -0.24% | 41% | -1.36% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how XENE ranks against every other measured name →
That’s how XENE usually reacts — get an email when it moves on news →Email me when XENE moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to XENE's baseline. Nothing else.
Recent XENE events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors | Press release | GlobeNewswire | +0.25% | +0.83% | |
| Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.72% | -1.18% | |
| XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law | Press release | Business Wire | -1.83% | -7.47% | |
| Wolf Popper LLP Announces Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors | Press release | GlobeNewswire | -1.69% | -1.69% | |
| Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit | Press release | GlobeNewswire | -1.69% | -1.69% | |
| Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program | Press release | GlobeNewswire | -3.29% | -9.66% | |
| Xenon to Present at Wells Fargo Healthcare Conference | Press release | GlobeNewswire | +0.53% | -0.45% | |
| Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.22% | +0.64% | |
| Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026 | Press release | GlobeNewswire | +0.81% | -1.90% | |
| Form 10-Q Xenon Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.00% | +0.57% | |
| Form 8-K Xenon Pharmaceuticals For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +1.00% | +0.57% | |
| Xenon Reports Q2 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +1.00% | +0.57% | |
| Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -2.94% | -1.50% | |
| Xenon to Report Q2 2026 Financial Results on August 6, 2026 | Press release | GlobeNewswire | -0.20% | -1.99% | |
| Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.05% | -0.40% | |
| Form 8-K Xenon Pharmaceuticals For: Jun 02 | SEC filing · Form 8-K | SEC EDGAR | +1.12% | -0.95% | |
| Form S-8 Xenon Pharmaceuticals | SEC filing · Form S-8 | SEC EDGAR | +1.12% | -0.95% | |
| Form S-8 POS Xenon Pharmaceuticals | SEC filing · Form S-8 | SEC EDGAR | +1.12% | -0.95% | |
| Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.35% | -1.87% | |
| Form 10-Q Xenon Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.63% | +0.55% | |
| Form 8-K Xenon Pharmaceuticals For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +0.63% | +0.55% | |
| Xenon Reports Q1 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.63% | +0.55% | |
| Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.15% | +2.76% | |
| Xenon to Report Q1 2026 Financial Results on May 7, 2026 | Press release | GlobeNewswire | +2.66% | -0.46% | |
| Form ARS Xenon Pharmaceuticals For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.17% | -2.19% | |
| Form DEF 14A Xenon Pharmaceuticals For: Apr 22 | SEC filing · Form DEF | SEC EDGAR | +1.17% | -2.19% | |
| Form DEFA14A Xenon Pharmaceuticals | SEC filing · Form DEFA14A | SEC EDGAR | +1.17% | -2.19% | |
| Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting | Press release | GlobeNewswire | -2.43% | -4.16% | |
| Xenon to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | -0.42% | -1.37% | |
| Form 8-K Xenon Pharmaceuticals For: Apr 07 | SEC filing · Form 8-K | SEC EDGAR | +0.80% | +1.82% | |
| Form S-8 Xenon Pharmaceuticals | SEC filing · Form S-8 | SEC EDGAR | +0.80% | +1.82% | |
| Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting | Press release | GlobeNewswire | +0.05% | +0.70% | |
| Form 8-K Xenon Pharmaceuticals For: Mar 13 | SEC filing · Form 8-K | SEC EDGAR | +2.34% | -0.62% | |
| Form 8-K Xenon Pharmaceuticals For: Mar 10 | SEC filing · Form 8-K | SEC EDGAR | +0.83% | -4.92% | |
| Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares | Press release | GlobeNewswire | +0.83% | -4.92% | |
| Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering | Press release | GlobeNewswire | -2.54% | -3.40% | |
| Form 8-K Xenon Pharmaceuticals For: Mar 09 | SEC filing · Form 8-K | SEC EDGAR | +2.18% | +3.86% | |
| Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS) | Press release | GlobeNewswire | +2.18% | +3.86% | |
| Xenon Pharmaceuticals Announces Proposed Public Offering | Press release | GlobeNewswire | -5.31% | -4.99% | |
| Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026 | Press release | GlobeNewswire | +2.18% | +3.86% | |
| Form 8-K Xenon Pharmaceuticals For: Feb 27 | SEC filing · Form 8-K | SEC EDGAR | +1.70% | -0.05% | |
| Form 10-K Xenon Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.29% | -3.59% | |
| Form 8-K Xenon Pharmaceuticals For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | +1.29% | -3.59% | |
| Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +1.29% | -3.59% | |
| Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.37% | +5.12% | |
| Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | -1.98% | -3.03% | |
| Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | -0.93% | -5.09% | |
| Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025 | Press release | GlobeNewswire | +0.08% | +0.04% | |
| Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.08% | +0.04% | |
| Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025 | Press release | GlobeNewswire | +0.31% | +3.05% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the XENE section they belong to.
Where else XENE is measured.
XENE earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| AtriCure, Inc. (ATRC) | 276 | +0.04% | 51% |
| Coherus Oncology, Inc. (CHRS) | 276 | +0.21% | 51% |
| Aclaris Therapeutics, Inc. (ACRS) | 275 | 0.00% | 48% |
| Anika Therapeutics Inc. (ANIK) | 275 | +0.07% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Xenon Pharmaceuticals Inc. - Common Shares's median reaction calculated?
Every labeled XENE news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 276 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 50% of XENE's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does XENE's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.